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Maternal immune activation results in complex microglial
transcriptome signature in the adult offspring that is
reversed by minocycline treatment
D Mattei1,13, A Ivanov2,3,13, C Ferrai4, P Jordan1, D Guneykaya1, A Buonﬁglioli1,5, W Schaafsma6, P Przanowski7, W Deuther-Conrad8,
P Brust8, S Hesse9,10, M Patt9, O Sabri9, TL Ross11, BJL Eggen6, EWGM Boddeke6, B Kaminska7, D Beule2,12, A Pombo4,
H Kettenmann1 and SA Wolf1
Maternal immune activation (MIA) during pregnancy has been linked to an increased risk of developing psychiatric pathologies
in later life. This link may be bridged by a defective microglial phenotype in the offspring induced by MIA, as microglia have key
roles in the development and maintenance of neuronal signaling in the central nervous system. The beneﬁcial effects of the
immunomodulatory treatment with minocycline on schizophrenic patients are consistent with this hypothesis. Using the MIA
mouse model, we found an altered microglial transcriptome and phagocytic function in the adult offspring accompanied by
behavioral abnormalities. The changes in microglial phagocytosis on a functional and transcriptional level were similar to those
observed in a mouse model of Alzheimer’s disease hinting to a related microglial phenotype in neurodegenerative and psychiatric
disorders. Minocycline treatment of adult MIA offspring reverted completely the transcriptional, functional and behavioral deﬁcits,
highlighting the potential beneﬁts of therapeutic targeting of microglia in psychiatric disorders.
Translational Psychiatry (2017) 7, e1120; doi:10.1038/tp.2017.80; published online 9 May 2017
INTRODUCTION
In recent years, microglia as the brain’s intrinsic immune cells have
emerged as having new roles in the pathophysiology of
psychiatric disorders such as schizophrenia.1 Signs of their
involvement stem from human postmortem and positron emis-
sion tomography studies indicating altered microglial cell density
and binding to the translocator protein (TSPO) in the brains of a
subset of schizophrenic patients.2–4 Microglia are able to
phagocytose synaptic material in the process of synaptic pruning,
which is essential for the proper development and maintenance
of brain circuitry.5 Their phagocytic activity also controls the pool
of neuronal progenitor cells during development and in
adulthood.6,7 As schizophrenia is a disorder with prominent
abnormalities in synaptogenesis,8 neurogenesis9,10 and neuronal
transmission,8,11 it is plausible that microglial dysfunction results
in aberrant synaptogenesis and neurogenesis in the developing
central nervous system, contributing to the development and
progression of schizophrenia. Epidemiological studies have linked
prenatal inﬂuenza infections with an increased risk of developing
schizophrenia in the offspring.12,13 Injection of the viral mimic
polyinosinic:polycytidilic acid (Poly(I:C)) to pregnant rodent dams
has been shown to induce a series of behavioral, morphological,
cytoarchitectural and biochemical changes in the brain of adult
offspring, which are highly comparable to the abnormalities
observed in human schizophrenic patients.14,15 The maternal
immune activation (MIA) in humans and animal models alike
could impact on the fetal microglia and result in functional
changes that are retained in adulthood.
Several clinical case reports have suggested that minocycline
alleviates mainly negative symptoms in schizophrenic patients.
Subsequent clinical trials were initiated to test the potential of the
drug as an add-on therapy for schizophrenia. In spite of the
accumulating data showing beneﬁcial effects of minocycline
treatment on both human patients16–22 and in animal models of
schizophrenia,23,24 a mechanistic insight into the action of
minocycline is lacking at present. It is suggested that minocycline
interferes with microglial activation; however, its actions may be
nonselective to microglial function. Chronic inﬂammation and, in
particular, MIA could be a major factor that contributes to the
development of neurodegenerative disorders such as Alzheimer’s
disease.25–27 Lahiri et al.28 proposed a 'Latent Early-life Associated
Regulation' model, postulating that latent changes in the
expression of speciﬁc genes initially primed at the developmental
stage of life. However, the involvement of microglia in neurop-
sychiatric diseases is unclear.
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Therefore, using the maternal immune activation model, we
investigated the effects of minocycline treatment on the
phenotype of hippocampal microglia derived from adult male
offspring. We also compared these data sets to the ones obtained
from an Alzheimer’s disease mouse model. We focused here on
the hippocampus as it is a structure particularly affected in
schizophrenia, and its malfunction contributes to the appearance
of positive, negative and cognitive symptoms.29–32
MATERIALS AND METHODS
Animals
The C57BL/6 mice were handled according to governmental (LaGeSo) and
internal (MDC) rules and regulations (animal protocol number G O196/12).
Day one of pregnancy was calculated from the day of appearance of a
vaginal plug. Pregnant dams were injected once intraperitoneally with
either Polyinosinic:polycytidylic acid (5 mg kg− 1 Poly(I:C) VacciGrade,
Invivogen, San Diego, CA, USA) or 0.9% saline solution at gestational day
15 (G15, Figure 1a). Despite its advantages, there are also limitations to the
Poly(I:C)-based MIA animal paradigm. Apart from the ‘traditional’, general
concerns relating to the usage of rodent systems to model complex
neuropsychiatric disorders, which present with alterations of inherently
‘human’ behavioral features, there are also experimental constrains of Poly
(I:C)-assisted MIA that need to be considered. The major drawback of using
immunogenic manipulations based upon Poly(I:C), rather than live
pathogens, is the—albeit well-characterized—limited set of immune
responses elicited. Comparatively, stimulating the maternal immune
system by administration of a real virus (such as inﬂuenza), leads to a
much broader activation of not only the innate, but also the acquired
immune system, thus more closely resembling the situation following
infection during pregnancy in humans. To ensure a least of ﬁve animals per
group for every set of experiments, an average of 10 dams per group (Poly
(I:C) and saline injected) was used. Male offspring were weaned at
postnatal day 21 (P21) and they were caged in a random manner so as to
avoid confounding litter effects. The mice were left undisturbed until the
day of behavioral phenotyping with the prepulse inhibition (PPI) test at
P60. The latter was used as a selection criteria so that only the Poly(I:C)
mice displaying deﬁcits in PPI were selected for further experiments. In
Supplementary Figure 3, we show all animals tested with PPI and indicate
the ones that were included for further analysis. The mice were kept in an
animal facility with 12 h of light and dark cycle with food and water ad
libitum.
Minocycline treatment
Minocycline (Sigma-Aldrich, Munich, Germany) was dissolved in drinking
water at 3 mg kg− 1 per day assuming an average consumption of 5 ml
water per day per animal. The dose was selected on the basis of the oral
dosage given to schizophrenic subjects in clinical trials (200 mg per day
assuming 70 kg weight, reviewed in ref. 33). Minocycline treatment was
started at postnatal day (P)70–P80 after the assessment of the baseline
behavioral deﬁcits, and was carried out for 5 weeks and throughout the
behavioral testing period (Figure 1a). On treatment, the mice were
randomly divided into the following groups: (Ctr), Controls—offspring from
NaCl-treated dams; Poly—offspring of Poly(I:C)-treated dams; and Poly/
Mino—offspring from Poly(I:C)-treated dams that received minocycline as
adults. We have previously reported that the minocycline treatment given
to control animals did not affect the sensorimotor gating, adult
hippocampal neurogenesis, microglial cell density and cytokine expression
pattern.23
Behavioral testing
Previous work conducted on Poly(I:C) offspring showed that they start to
display behavioral deﬁcits at the switch between adolescence and early
adulthood, as it is the case in human schizophrenic patients (reviewed in
ref. 34). This age corresponds in mice to P60. We therefore started the
behavioral battery tests at P60. The behavioral testing was performed by a
person blind to the experimental groups.
Prepulse inhibition
The PPI of startle reﬂex was assessed using a standard startle chamber
(Figure 1b, SR-Lab, San Diego Instruments, San Diego, CA, USA) according
to the manufacturer's protocol. The session starts with 5 min habituation
where the mouse is exposed to white noise at 65 decibel (dB). Afterwards,
a pseudorandomized session started with 10 different types of trials: 8
acoustic startle pulse alone (120 dB) and 10 different prepulse followed by
pulse trials were applied in which either 69, 73 or 81 dB stimuli were
presented 100 ms before the pulse. Intertrial intervals of a random
duration of 10–25 s (65 dB white noise) separated the trials. In the prepulse
plus startle pulse trials, the amount of PPI is measured and expressed as
percentage of the basal startle response (startle pulse alone).
Novel object recognition test
The test was performed in a square-shaped open-ﬁeld box with high walls
(72× 72 × 33 cm, Figure 1d). The test was performed as described
elsewhere, but with some modiﬁcations.35 The test starts with a 5 min
habituation session. After an intertrial interval of 5 min, the mouse is
allowed to explore two different objects for 5 min. After an intertrial
interval of 5 min, the mouse was allowed to explore the same arena for
3 min containing one old and one novel object (Figure 1d). The
measurements were performed through the Anymaze software (ANY-
maze 4.50, Stoelting Europe, Dublin, Ireland). To assess the detection of
novelty, we calculated the percentage of time spent by the mice exploring
the novel object (NO) as compared with the total time spent in exploring
the new and old object (OB):
(NOExplorationTime/(NOExplorationTime+OBExplorationTime)) × 100. The open ﬁeld
and the objects were cleaned with 5% ethanol after each mouse was
tested, to avoid olfactory cues.
Sociability test
To assess the social behavior of the mice, the sociability test was
performed in a tripartite chamber, composed of three chambers of equal
size (20 × 40 cm, Figure 1f). After habituation for 5 min in the middle
chamber, two cylindrical cages, one empty and one containing a stranger
mouse were placed in the lateral chambers. The mouse was given then
free access to all chambers for a total of 10 min (ANY-maze 4.50, Stoelting
Europe). The preference for the stranger mouse (S) toward the empty cage
(E) was assessed by calculating the percentage of time spent making
contact with the stranger mouse over the sum of time spent with both the
S and the E: (STimeMakingContact/(STimeMakingContact+ETimeMakingContact)) × 100.
The cages and chambers were wiped clean with 5% ethanol after each
mouse to avoid olfactory cues.
Magnetic cell sorting of microglial cells
The mice were deeply anesthetized with pentobarbital (Narcoren, Merial,
Hallbergmoos, Germany) and perfused with ice-cold phosphate-buffered
saline. After decapitation, the head was removed and the brain retrieved
and put immediately in ice-cold Hank's balanced salt solution (GIBCO,
Invitrogen, Karlsruhe, Germany). Tissue dissection and microglial isolation
were performed as described elsewhere.36 Brieﬂy, the pelleted single-cell
suspension of the hippocampi was resuspended in ice-cold percoll solution
composed of myelin gradient buffer plus percoll (GE Healthcare, Little
Chalfont, Buckinghamshire, UK) and a layer of phosphate-buffered
saline was carefully applied on top. The tubes were then centrifuged at
950 g, 4 °C low brake and acceleration. The cells were resuspended and
washed in ice-cold magnetic cell sorting (MACS) buffer (phosphate-
buffered saline, 0.5% bovine serum albumin, 2 mM EDTA) followed by
incubation with anti-mouse CD11b magnetic beads (Miltenyi Biotech,
Bergisch Gladbach, Germany) at 4 °C for 15 min. The cells were
resuspended in MACS buffer and passed through medium-sized MACS
columns (Miltenyi Biotech) attached to a magnet. The ﬂow-through was
discarded and the cells were ﬂushed out of the column in MACS buffer,
pulled down by centrifugation and resuspended in 1 ml TRIzol (Thermo
Scientiﬁc, Schwerte, Germany) snap frozen in liquid nitrogen and stored at
− 80 °C until library preparation.
mRNA library preparation and sequencing
The messenger RNA (mRNA) libraries were made using TruSeq RNA Sample
Preparation Kits v2 setA (#RS-122-2001, Illumina, San Diego, CA, USA)
following the manufacturer's instructions. RNA-sequencing (RNA-seq) was
performed on mRNA extracted from freshly isolated microglia (as
described above) from the hippocampi of control, Poly(I:C) and
minocycline-treated Poly(I:C) animals. The Poly(I:C) animals used for the
RNA-seq were chosen on the basis of their deﬁcit in PPI compared with
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control animals (Supplementary Figure 1a). A group of Poly(I:C) animals
were treated with minocycline (3 mg kg− 1 per day) for 5 weeks and re-
tested for PPI to conﬁrm the efﬁcacy of minocycline on this schizophrenic
endophenotype. A total amount of six animals per group were used. To
obtain a substantial number of microglial cells, hippocampi were pooled
together from three animals per group for a ﬁnal number of two biological
replicates per group. The complementary DNA (cDNA) libraries were
loaded onto a HiSeq Rapid PE Flow Cell (Illumina) and mRNA-seq libraries
were sequenced paired-end (2 × 100 bp) using a HiSeq 2500 sequencer
(Illumina).
Quantitative PCR
For quantitative PCR validation of selected genes, we used the RNA
extracted for the sequencing experiment. First-strand cDNA synthesis was
done with the SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA,
USA) using oligo-dT primers12–18 (Invitrogen) according to the manufac-
turer’s instructions. Quantitative real-time PCR reactions were performed in
a 7500 Fast Real-Time thermocycler (Applied Biosystems, Carlsbad, CA,
USA) using the SYBR Select Master Mix (Applied Biosystems) according to
the manufacturer’s instructions. cDNA input ranged between 1 and
5 ng μl− 1 of total RNA transcribed into cDNA. The expression data were
Figure 1. Poly(I:C) mice show correlates of positive, negative and cognitive symptoms, which are rescued by chronic minocycline treatment.
(a) Representative image showing the experimental design. Pregnant dams were injected at gestational day 15 (G15) with either saline
solution or Poly(I:C). The offspring was tested for behavioral deﬁcits at postnatal day 60 (P60). Poly(I:C) animals were then subjected to
minocycline treatment (3 mg kg− 1 per day) for 5 weeks. They were then re-tested for the same behavioral battery at the end of the treatment.
(b) Representation of the apparatus used for the prepulse inhibition test (PPI). (c) Part of the adult offspring of Poly(I:C)-challenged dams
exhibited deﬁcits in sensorimotor gating as measured through the PPI test for all three prepulses tested, (69, 73 and 81 dB prepulses).
Minocycline treatment signiﬁcantly restored the percentage of PPI for all three prepulses (n= 7 Poly(I:C) mice before and after minocycline
treatment and 14 controls). (d) Representative image of the apparatus used for the novel object recognition test. (e) Poly(I:C) mice showed
working memory impairments in the novel object recognition task, displayed as a signiﬁcantly decreased percentage of time spent making
contact with a new object as compared with control animals. Five-week minocycline treatment signiﬁcantly increased their ability to detect a
novel object. (n= 16 Poly(I:C) mice before and after minocycline treatment and 14 controls). (f) Representative image of the apparatus used for
the sociability test. (g) Poly(I:C) mice display deﬁcits in social behavior shown as decreased percentage of time spent making contact with a
stranger mouse as compared with controls. Five-week minocycline treatment signiﬁcantly restored a normal social pattern in these mice
(n= 16 Poly(I:C) mice before and after minocycline treatment and 14 controls). Error bars indicate s.e.m. in all the panels. The PPI data were
analyzed by two-way analysis of variance (ANOVA) followed by Bonferroni post hoc test, while the novel object recognition test and the
sociability data by one-way ANOVA followed by Bonferroni post hoc test. *Po0.05, **Po0.001, ***Po0.0001. Ctrl, control animals; dB, decibel;
G15, gestational day 15; Obj, object; Poly, Poly(I:C) animals; Poly/Mino, Poly(I:C) animals treated with minocycline; PPI, prepulse inhibition.
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Figure 2. The decrease in phagocytosis and related genes are similar in the MIA and the APP/PS1 model and rescued by minocycline
treatment. (a) Representative image of the gating strategy used for the FACS analysis of microglia that phagocytosed ﬂuorescent latex beads
within 30 min. (b) Representative histograms from the three experimental groups. The peaks represent the number of microglia that
phagocytosed one, two or three beads. (c) Graph showing the phagocytic index, which represents the total numbers of cells that
phagocytosed and the number of beads taken up by a given cell. As the graph indicates, hippocampal microglia have a decreased phagocytic
index in Poly(I:C) animals (n= 12 mice) as compared with controls (n= 17 mice). Microglial cells isolated from hippocampi of Poly(I:C) mice
treated with minocycline showed a normal phagocytosis, comparable to control animals and signiﬁcantly higher as compared with untreated
Poly(I:C) mice (n= 11 mice). (d) Scatter plot showing the comparison of the differential expression in APP/PS1 and Poly(I:C) mice. The x axis
represents the log2 fold changes between Poly(I:C) and control mice, y axis represent the log2 fold changes between APP/PS1 and control
mice. The differentially expressed genes in these two animal models correlate signiﬁcantly (Pearson’s correlation= 0.59). (e) The Venn diagram
shows the overlap of signiﬁcantly differentially expressed genes between APP/PS1 versus control and Poly(I:C) versus control (for both data
sets adjusted P-value o0.01). We found 248 genes to be signiﬁcantly deregulated in both animal models as compared with their respective
controls. P-value for the overlap was calculated with Fisher's exact test (see the 'Materials and methods' section). (f) Schematic representation
of the pathways involved in microglial phagocytosis on different stimuli. Orange represents examples of genes found to be deregulated in
microglial from both the APP/PS1 and Poly(I:C) model. **Po0.001, ***Po0.0001. APP, APP/SP1 mice; ctr, controls; FACS, ﬂuorescence-activated
cell sorting; MIA, maternal immune activation; NS, not signiﬁcant; Poly, Poly(I:C) mice.
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normalized to beta-actin. The primers used are listed in Supplementary
Material 1.
Computational analysis
Paired-end RNA-Seq reads were mapped to the mouse reference genome
GCRM38/mm10 with STAR,37 using the following parameters ‘--out-
FilterMultimapNmax 20 --alignSJoverhangMin 8 --alignSJDBoverhangMin
1 –outﬁlterMismatchNmax 999 --outFilterMismatchNovelLmax 0.04
--alignIntronMin 20 --alignIntronMax 10^6 --alignMatesGapMax 10^6’.
Mapped read pairs were assigned to genes with feature Counts.38 We used
gencode version M6 (Ensembl 81) mouse genome annotation. Alternative
scaffolds, ﬁx- and novel- patches were removed from the analysis. To
identify differentially expressed genes between different conditions, we
used R/Bioconductor DeSeq2.39 The analysis was carried out with DeSeq2
default parameters, using raw read counts. Gene ontology (GO) analysis
was performed with topGO gene ontology tool, using the ‘elim’ algorithm
(nodes= 5; Alexa A and Rahnenfuhrer J 2016, topGO: Enrichment Analysis
for Gene Ontology, R package version 2.24.0.).
For the comparison of differential expression with APP mouse model, we
downloaded the log2 fold changes and the adjusted P-values from
Holtman et al.40 This (microarray) data set comprised 9938 genes of which
9813 could be matched with our Gencode M6 gene IDs. Among these,
1595 were differentially expressed in the APP model (using adjusted P-
value o 0.01). From 1398 differentially expressed genes between Poly and
control mice, 736 were present in the matched Holtman et al.40 data set
and 248 of these were also differentially expressed in the APP model (again
using adjusted P-value o0.01). The corresponding Fisher’s exact yields a
P-value of 3.8e− 34 and thus conﬁrms a strong overlap of differentially
regulated processes between the two models. PU.1 target genes were
retrieved from Satoh et al.41 As a background control, we selected the
same amount of genes that are not targeted by PU.1 but have a similar
expression distribution in control samples.
Data accessibility
Deep sequencing data are deposited on Sequence Read Archive
(BioProject: PRJNA341344 accession ids: SRR4244948, SRR4244949,
SRR4244950, SRR4244951, SRR4244952, SRR4244953) and will be released
on publication.
Immunohistochemistry and confocal microscopy
The detailed staining procedure was described elsewhere.23 For staining of
the ionized calcium-binding adaptor molecule 1 (Iba1) and CD18, free-
ﬂoating 40 μm thick sections were incubated in 10% donkey serum and
0.13% Triton-X in tris-buffered saline solution (TBSplus). The primary
antibodies were prepared in TBSplus at the following dilutions: rabbit anti-
Iba1 (Wako chemicals, Neuss, Germany, product code: 019-19741) 1:400;
rat anti-CD18 (Abcam, Cambridge, UK, ab119830) 1:350. The sections were
incubated with the primary antibodies overnight at 4 °C. The secondary
antibodies were also prepared in TBSplus at the following dilutions:
donkey anti-rabbit Cy3 (Dianova, Hamburg, Germany) 1:350; donkey
anti-rat Alexa Fluor 488 (Dianova). Nuclei were stained using DAPI
(4',6-diamidino-2-phenylindole), 1:500. The sections were incubated with
secondary antibodies at room temperature for 2 h. Confocal Z-stacks of
20 μm of thickness were taken with a Leica SPE confocal microscope (Leica,
Bensheim, Germany) through the dentate gyrus of the hippocampus at 20-
times magniﬁcation. Representative pictures were taken in the proximity of
the dentate gyrus at 20-times magniﬁcation. The stacks were transformed
into one picture using a Z-projection with maximum intensity using ImageJ
software.42 Mean ﬂuorescence intensity per area for each target (Iba1,
CD18, DAPI) throughout the dentate gyrus was measured by ImageJ and
divided by the mean ﬂuorescent intensity per area measured for DAPI and
averaged for all animals within each group. A total of two distinct
hippocampal slices per animal were sampled for the analysis. The images
were sampled and analyzed by a person blind to the group identity.
Enzyme-linked immunosorbent assay
Whole protein homogenates, from the hippocampi were obtained by
mechanical tissue disruption using a syringe in ice-cold phosphate-
buffered saline containing protease inhibitors (complete Ultra Tablet,
Roche, Basel, Switzerland). Protein concentration was evaluated by
NanoDrop 8000 spectrophotometer (Thermo Scientiﬁc, Waltham, MA,
USA). Complement component 4a (C4a) levels in hippocampal lysates were
measured using the mouse C4a enzyme-linked immunosorbent assay
(ELISA) kit (Elabscience Biotechnology, Wuhan, China), according to the
manufacturer’s manual. Detection of the cytokines was performed by
using the Multiplex Immunoassay ProcartaPlex (Affymetrix eBioscence,
Vienna, Austria). This beads-based ELISA allows the detection of the
concentration of up to 20 analytes using the Luminex xMAP (multi-analyte
proﬁling) technology. Speciﬁcally, the cytokines pattern included tumor
necrosis factor-α and interleukin-6 (IL-6; mouse High-Sensitive Assay)
combined with IL-1β (Mouse Assay).
Flow cytometry-based phagocytosis assay
Microglia were isolated from the hippocampi and puriﬁed via MACS as
described above. After isolation, they were resuspended in Dulbecco's
Modiﬁed Eagle Medium (GIBCO, Invitrogen) supplemented with 10% fetal
calf serum, 2 mM L-glutamine, 37 °C. The cells were then seeded onto
primary cultured neonatal astrocytes overnight. Fluoresbrite Carboxylate
Micropheres (BrightBlue, 4.5 μm) were coated with 5% fetal calf serum for
30 min at room temperature, 1000 r.p.m. The beads were resuspended in
Hank's balanced salt solution at a ﬁnal concentration of 2 × 106 beads per
ml. Microglia-astrocyte co-cultures were washed once with Hank's
balanced salt solution before 1 ml bead solution was applied. The cells
were incubated with the beads for 30 min at 37 °C. Afterwards, they were
collected and washed in ﬂuorescence-activated cell sorting buffer. The
cells were stained with: CD11b, 1:50 (eBioscience, San Diego, CA, USA) for
15 min at 4 °C. After staining, the cells were washed in ﬂuorescence-
activated cell sorting buffer and pulled down at 500 g for 5 min. The cells
were resuspended in a propidium iodide solution (1:200 in ﬂuorescence-
activated cell sorting buffer) to stain dead cells. The stained cells were
transferred to a BD LSRFortessa Flow cytometer (BD Bioscience,
Heidelberg, Germany). The phagocytic index as shown in Figure 2c
implements the total number of cells that phagocytosed and the number
of beads taken up by a given cell. The data were analyzed using FlowJo
v10 software (Tree Star, Ashland, OR, USA).
In vitro autoradiography
For the synthesis of [18F]GE180, [18F]ﬂuoride was produced at a
Scanditronix MC35 cyclotron via the nuclear reaction 18O(p,n)18F by
proton bombardment of a 18O-water target, transferred to a shielded
hotcell by a stream of argon and trapped on a QMA SepPak SPE cartridge
(Waters, Eschborn, Germany, preconditioned with potassium bicarbonate).
The [18F]ﬂuoride was eluted by Kryptoﬁx 2.2.2 (4 mg, 10 μmol) and
potassium bicarbonate (1 mg, 10 μmol) in a mixture of water (0.5 ml) and
acetonitrile (0.5 ml) into a sealed reaction vessel. This reaction mixture was
dried under a stream of argon at 100 °C. Subsequently, without prior
cooling of the mixture, the mesylate precursor (GE Healthcare; 0.5–1.0 mg)
dissolved in 1 ml acetonitrile (absolute) was added, followed by 10 min of
heating at 100 °C. After brief cooling, the mixture was diluted by 3.5 ml
water and injected into the high-performance liquid chromatography
system (Hichrom ACE 5 C18 columns, 5 μm, 100× 10 mm) for puriﬁcation.
The product fraction was diluted with water (20 ml) and passed over a tC18
SepPak SPE cartridge (Waters, preconditioned with ethanol and water).
After washing the cartridge with water (3 ml), the product was eluted with
ethanol (0.5–1.0 ml) and formulated by further dilution with saline.
Sagittal brain sections (16 μm thick) from mice in control, Poly(I:C) and
minocycline-treated Poly(I:C) animals were obtained by cryosectioning,
mounted on microscopic glass slides and stored at − 80 °C until the day of
the experiment. The frozen brain sections were dried at room temperature
in a stream of cold air, preincubated with 50 mM Tris-HCl, pH 7.4/21 °C at
room temperature for 15 min and dried again before incubation with [18F]
GE180 (0.17 MBq ml− 1 50 mM Tris-HCl, pH 7.4/21 °C, containing 120 mM
NaCl, 5 mM KCl, 2 mM MgCl2, 1 mM CaCl2; 2.5 nM at the start of the
incubation) at room temperature for 60 min. Nonspeciﬁc binding of [18F]
GE180 was determined by co-incubation with both 20 μM GE180 and 20 μM
PK11195. After incubation, the sections were washed two times for 2 min
with ice-cold 50 mM Tris-HCl, pH 7.4/4 °C and rinsed in ice-cold distilled
water to remove the buffer salts. The slides were dried in a stream of cold
air at room temperature and exposed to 18F-sensitive imaging plates (BAS
2025, Fujiﬁlm, Tokyo, Japan). The imaging plates were scanned in a CR 35
Bio (Dürr NDT, Bietigheim-Bissingen, Germany) scanner with a pixel size of
12.5 μm×12.5 μm. Binding of [18F]GE180 was quantiﬁed by measuring
the optical density in hand-drawn region of interest (the hippocampus) on
the respective autoradiogram. The images were analyzed using Aida
Image Analyzer v. 4.27 (raytest, Elysia Germany, Straubenhardt, Germany).
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Speciﬁc binding was calculated as total binding minus nonspeciﬁc binding
for the same region in the adjacent sections. The analysis of the
radioligand-binding potential was performed by a person blind to the
experimental groups.
Statistical analysis
To assess statistical differences, we used Prism 5 for Windows (Graphpad
Software, La Jolla, CA, USA). For the PPI tests, we performed a two-way
repeated-measures analysis of variance (ANOVA) to test for the effect of
phenotype (Poly(I:C)) and treatment (minocycline) across the whole session
followed by Bonferroni post hoc test. For the analysis of the remaining
behavioral tests, the phagocytosis assay, the radioligand-binding assay,
ELISA and immunohistochemically data a one-way ANOVA (when the data
showed a normal distribution) followed by either Bonferroni post hoc test
or Newman–Keuls post hoc test were performed. The variance between the
groups was estimated through Bartlett's test for equal variances whenever
the sample size was equal or bigger than 7. For smaller sample size,
estimation was given based on the number of animals and standard
deviation.
RESULTS
Minocycline treatment rescues correlates of positive, negative and
cognitive symptoms in adult Poly(I:C) animals
In the ﬁrst set of experiments, we explored the effect of a chronic
minocycline treatment on mouse behavioral traits similar to
positive, negative and cognitive symptoms displayed by human
schizophrenic patients. We used 16 Poly(I:C) animals and 14
controls for behavioral testing. Sensorimotor gating can be
measured via the PPI of the startle reﬂex test in both humans and
rodents.14,43 Out of the 16 Poly(I:C) mice, 7 showed a robust deﬁcit
in sensorimotor gating (at 69, 73 and 81 dB prepulses; two-way
ANOVA, F(2,66) = 48.44, Po0.0001, Bonferroni's post hoc test,
Poly versus controls, Po0.0001 for all three prepulses,
Figures 1b and c). After 5 weeks of minocycline treatment
(3 mg kg− 1 per day), the same mice displayed a signiﬁcant rescue
in sensorimotor gating (n= 7 Poly(I:C) mice before and after
minocycline treatment and 14 controls, Bonferroni post hoc test
Poly/Mino versus Poly, Po0.001 for the response to 69 dB
prepulse, Po0.0001 for the response to 73 dB prepulse and
Po0.001 for the response to 81 dB prepulse, Figures 1b and c).
There was no difference in the response to the pulse of 120 dB
alone across all tested groups and cohorts (Supplementary
Figure 2). For the cognitive symptoms domain, we used the
novel object recognition test for working memory.44 Poly(I:C) mice
displayed working memory deﬁcits in the novel object recognition
test (Figures 1d and e), where their percentage of exploration
of the new object over the total exploration of the objects
(42%±8.8) was signiﬁcantly lower compared with controls
(81%±4.3). Minocycline treatment signiﬁcantly improved their
ability to discriminate a novel object from a familiar one (69%±4.2,
n= 16 Poly(I:C) mice before and after minocycline treat-
ment and 14 controls, one-way ANOVA, F(2,36) = 10.2, P= 0.0003,
Bonferroni post hoc test Poly versus control Po0.0001 and Poly
versus Poly/Mino Po0.05). For readout of a negative-like
symptom, we assessed social behavior. Poly(I:C) mice displayed
deﬁcits in social behavior (Figures 1f and g), shown as a
signiﬁcantly decreased percentage of time making contact with a
stranger mouse (58%±3.8) as compared with controls (72%±3.8).
After minocycline treatment, the percentage of time the mice
spent with the stranger mouse normalized to control levels
(70%±2.1, n= 16 Poly(I:C) mice before and after minocycline
treatment and 14 controls, one-way ANOVA, F(2,43) = 7.41,
P= 0.0017, Bonferroni post hoc test Poly versus control Po0.05
and Poly versus Poly/Mino Po0.001). These results show
similarities to the ﬁndings in human clinical trials of minocycline
treatment alleviating negative, positive and cognitive symptoms in
patients with schizophrenia.16–18,20,21 As deﬁcits in rodent PPI
reliably suggest a behavioral phenotype associated with schizo-
phrenia in Poly(I:C) mice, we used this test to select only mice with
a PPI deﬁcit for all further experiments within this study.
Supplementary Figures 1a–d show the ﬁnal selection of the Poly
(I:C) cohorts after minocycline treatment used for every experiment
performed in this study. Supplementary Figures 3a–e show the
single data points of the percentage of PPI for the initial selection
for Poly(I:C) versus control mice before minocycline treatment.
Figure 3. Hippocampal microglial cells from Poly(I:C) mice show a
profoundly altered transcriptome signature. (a) Hierarchical cluster-
ing of the read counts of the differentially expressed genes between
Poly(I:C) and control mice (adjusted P-value o0.01). The genes in
cluster 1 were signiﬁcantly downregulated in microglia from Poly(I:
C) mice as compared with controls. The genes pertaining to cluster 2
were upregulated. Minocycline treatment brings the expression
levels of genes in these clusters to a level similar to controls. Beside
the clusters are displayed examples of biological processes
associated with the genes within the clusters. (b) Empirical
cumulative distribution function of the log2 fold changes of PU.1
target genes as well as non-target (expression matched) control
genes. Genes targeted by PU.1 are selectively downregulated in Poly
animals and minocycline treatment shifts back the expression
pattern of these genes to normal levels. Kolmogorov–Smirnov two-
sided test was used to calculate the P-values. Two biological
replicates per group were used for the sequencing, where every
replicate is a pool of microglia from the hippocampi of three mice.
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Hippocampal microglial cells from Poly(I:C) mice show an altered
transcriptome signature that is rescued by minocycline treatment
To obtain a comprehensive overview of the pathways involved in
the microglial phenotype associated with maternal immune
activation during pregnancy, we performed a mRNA-seq of
freshly isolated microglia from the hippocampi of adult male
Poly(I:C) mice, Poly(I:C) mice treated with minocycline and control
animals. A total of six animals per group were used. To obtain a
substantial number of microglial cells, hippocampi were pooled
together from three animals per group for a ﬁnal number of two
biological replicates per group. We selected Poly(I:C) animals with
a signiﬁcant deﬁcit in PPI (Supplementary Figures 1a and 3b). In
total, we obtained between 19.8 and 26.9 million paired-end reads
per sample with 83%–91% concordant pair alignment rate (see
the 'Materials and methods' section). The comparison of the
replicates demonstrated a high reproducibility of the data
(Supplementary Figure 4a). Notably, further comparison of the
samples showed that the mRNA expression proﬁle of the two
minocycline-treated Poly(I:C) samples were similar to the control
samples, while the proﬁle of both Poly(I:C) samples were distant
from the latter groups (Supplementary Figure 4b). Differential
expression analysis revealed that microglia derived from the
hippocampi of adult Poly(I:C) mice presents with wide-scale
changes in transcriptome relative to control. We identiﬁed 1398
signiﬁcantly deregulated genes (adjusted P-value cutoff o0.01),
of which 402 were upregulated and 563 downregulated more
than two fold. When comparing hippocampal microglia from Poly
(I:C) mice treated with minocycline and untreated Poly(I:C) using
the same cutoff as above, we found 943 deregulated genes of
which 441 were upregulated and 193 downregulated more than
twofold. However, we found only 21 genes to be signiﬁcantly
deregulated, when comparing microglial cells from minocycline-
treated Poly(I:C) mice and controls already showing that mino-
cycline normalized the Poly(I:C)-associated microglia phenotype
towards the naive microglial phenotype (Figure 3a, Supplementary
Table 1). To identify the deregulated biological processes in
Poly(I:C) mice, we separately subjected the up- (cluster 2) and
downregulated (cluster 1) genes to Gene Ontology analysis.
In cluster 1, we found signiﬁcant enrichment of genes
associated with processes such as inﬂammatory response, cell
migration and phagocytosis (Figure 3a; for a complete overview of
the gene ontology analysis, see Supplementary Table 2a). Of
particular interest are the downregulated genes that encode for
cell surface receptors associated with ‘pro-phagocytic’ signals that
initiate and regulate phagocytosis. These genes include Fcgr1,
Itgav and P2ry6 (Figure 3a, Supplementary Table 1). Interestingly,
genes also encoding microglial surface receptors that sense
neuronal ‘anti-phagocytic’ signals, including Sirpa, Siglece and
Cx3cr1 were downregulated (Figure 3a, Supplementary Table 1). In
cluster 2, we found signiﬁcant enrichment of genes associated
with extracellular matrix organization, embryonic development,
positive regulation of long-term neuronal plasticity and angiogen-
esis (Figure 3a, Supplementary Table 2a).
In cluster 1, we detected a signiﬁcant deregulation of Spi1, Irf8
and Jun (Supplementary Table 1) that we validated via quantita-
tive PCR comparing their relative expression to transcripts per
million values obtained from the mRNA-seq (Supplementary
Figures 4c and d). Importantly, Spi1 and Irf8 transcription factors
may act as master switches responsible for such a drastic change
in the microglial phenotype as they are crucial for microglial
development and maintenance.41,45,46 Adult minocycline treat-
ment restored the mRNA levels of these two transcription factors.
In particular, Spi1, which encodes the transcription factor PU.1,
may control around 5000 genes in microglia.41 We therefore
compared the differential expression of previously published PU.1
target genes41 to expression-matched controls. This com-
parison demonstrated that PU.1 target genes were signiﬁcantly
downregulated in Poly(I:C) mice and restored on minocycline
treatment (Figure 3b). We therefore hypothesize that the drastic
changes in microglial transcriptome may arise from the down-
regulation of PU.1 expression along with its target genes.
Increased pro-inﬂammatory signaling in Poly(I:C) hippocampal
microglia
Studies conducted so far in vivo and in postmortem human brains
and in the Poly(I:C) model of schizophrenia reported upregulation
of classical markers of microglial activation such as increased
binding of radioligands to the TSPO and increased cytokine levels
(reviewed in refs 14,47). As our transcriptome analysis reveals a
marked general downregulation of genes involved in processes
related to immune cell activation, we analyzed whether these markers
are altered and whether minocycline prevents this alteration.
To determine region-speciﬁc TSPO binding, we performed an
autoradiographic study of hippocampal slices using the TSPO ligand
[18F]GE180.48 We used a strategy similar to the one adopted by
Kreisl et al.49 where the authors showed that schizophrenic patients
display an increased binding potential to the TSPO in postmortem
brain tissue relative to controls. These ﬁndings are similar to the
in vivo results utilizing positron emission tomography scans.50–52 We
selected male Poly(I:C) mice with PPI deﬁcits and randomly assigned
a group of these mice to minocycline treatment and investigated
the radioligand [18F]GE180 binding capacity (Supplementary Figures
1b and 3c). In Figure 4a, we show representative picture of a slice
from a control animal, used for the analysis of binding capacity
along with a slice labeled with Nissl stain to outline anatomical
structures (Figure 4b). Poly(I:C) mice have an increased binding
potential expressed as relative intensity of the signal detected from
the bound radioligand in the hippocampus as compared with
control animals (Poly, n=5, 808±63.4 versus controls, n=6,
399±87, Figure 4c). Minocycline treatment normalized the radi-
oligand [18F]GE180 binding potential in the hippocampus towards
control levels (Poly/Mino, n=6, 280±35.7, Figure 4c, one-way
ANOVA F(14,16) =5.64, P=0.016; Bonferroni's post hoc test Poly
versus controls and Poly/Mino versus Poly, Po0.05).
As a second indicator of activation, we determined the
immunoreactivity of Iba1.53 We found that Poly(I:C) animals
displayed a higher Iba1 immunoreactivity expressed as relative
intensity (11 ± 2, n= 7) as compared with controls (4.8 ± 1, n= 5),
while minocycline-treated mice showed an Iba1 immunoreactivity
comparable to controls (3.1 ± 0.6, n= 4, Figures 4d and e, one-way
ANOVA, F(2,13) = 6.41, P= 0.01, Newman–Keuls post hoc test Poly
versus controls and Poly versus Poly/Mino, Po0.05). Next, we
measured by means of ELISA the levels (pg/ng) of the following
cytokines in whole hippocampal tissue from control (n= 5),
Poly(I:C) (n= 5) and Poly(I:C)/Mino (n= 4) mice: IL-1β, IL-6 and
tumor necrosis factor-α (Figures 4f–h). We only observed a
signiﬁcant increase in IL-6 in Poly(I:C) hippocampal homogenates
(0.25 ± 0.022) as compared with controls (0.14 ± 0.016) that was
abolished in the Poly(I:C)/Mino group (0.16 ± 0.031, Figure 4h,
one-way ANOVA F(2,11) = 6.62, P= 0.013, Newman–Keuls post hoc
test Poly versus controls and Poly versus Poly/Mino, Po0.05). The
levels of IL-1β and tumor necrosis factor-α did not change
between groups (Figures 4f and g). For the PPI measurement of
this cohort, see Supplementary Figures 1d and 3e.
Decreased phagocytic activity displayed by Poly(I:C) hippocampal
microglia is rescued by chronic minocycline treatment
Our transcriptome analysis indicated that genes involved in
phagocytosis such as Spi1, Syk, Hck, Dock2 and Elmo1 are
downregulated (Supplementary Table 1). To determine phagocytic
activity on a functional level, we studied the incorporation of
ﬂuorescent latex beads within 30 min and quantiﬁed it by
ﬂuorescence-activated cell sorting analysis. Figure 2a shows the
gating strategy to determine the uptake of the beads. In Figure 2b,
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we show representative histograms from all three experimental
groups. The peaks represent the number of microglia that
phagocytosed one, two or three beads. A detailed gating strategy
is presented in Supplementary Figure 5. The phagocytosis assay
conducted on hippocampal microglia revealed that these cells have
a decreased phagocytic index in Poly(I:C) animals (0.58±0.06, n=12)
as compared with controls (1.0 ± 0.08, n=17, Figure 2c). Microglial
cells isolated from hippocampi of Poly(I:C) mice treated with
minocycline showed normal phagocytosis activity, comparable to
control animals and signiﬁcantly higher as compared with untreated
Poly(I:C) mice (0.91±0.04, n=11, Figure 2c, one-way ANOVA, F
(2,37)= 10.21, P=0.003, Bonferroni post hoc test controls versus Poly,
Po0.0001, Poly versus Poly/Mino, Po0.001). For the PPI measure-
ments of this cohort, see Supplementary Figures 1c and 3d.
Figure 4. Signs of classical pro-inﬂammatory activation in Poly(I:C) hippocampal microglia. (a) Representative image of a sagittal slice (from a
control animal) used for the analysis of the binding capacity with the TSPO-speciﬁc radioligand [18F]GE180. (b) Shows a representative image
of a Nissl-stained sagittal slice (control animal) used to localize speciﬁc brain regions. (c) Shows that Poly(I:C) mice exhibit an increased binding
potential to the TSPO in the hippocampus (n= 5 mice) with respect to controls (n= 6 mice). On the other hand, slices from Poly(I:C) mice
treated with minocycline display a normalized binding potential in the latter region (n= 6 mice), signiﬁcantly lower than untreated Poly(I:C)
animals and comparable to controls. (d) Representative pictures illustrating increased Iba1 immunoreactivity in the proximity of the DG of
Poly(I:C) mice as compared with controls and minocycline-treated mice. Pictures were taken at a 63-times magniﬁcation. (e) Iba1
immunoreactivity was increased in the dentate gyrus of the hippocampus (DG) of Poly(I:C) mice (n= 7) as compared with controls (n= 5). Poly
(I:C) animals treated with minocycline (n= 4) displayed a normal Iba1 immunoreactivity. (f–h) Enzyme-linked immunosorbent assay (ELISA)
measurement in whole hippocampal homogenates of the pro-inﬂammatory cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor
necrosis factor-α (TNF-α). Only IL-6 was found to be signiﬁcantly increased (h), while the levels of the other cytokines remained unchanged
(f and g; Controls, n= 5; Poly(I:C), n= 5; Poly(I:C) treated with minocycline, n= 4). Error bars represent s.e.m. in all the panels. The data from the
radioligand-binding assay were analyzed by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test. The data from the
immunoreactivity and ELISA were analyzed by one-way ANOVA followed by Newman–Keuls post hoc test. *Po0.05, **Po0.001. Cb,
cerebellum; Cc, corpus callosum; ctrl., control animals; Ctx, cortex; Hip, hippocampus; Ob, olfactory bulbs; Poly, Poly(I:C) animals; Poly/Mino,
Poly(I:C) animals treated with minocycline; Th, thalamus; TSPO, translocator protein.
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The phenotype of microglia derived from the MIA model is
comparable to the phenotype of microglia derived from the
APP/PS1 Alzheimer’s model
We previously demonstrated that microglia have decreased
phagocytic functions in two mouse models of Alzheimer’s disease
including the APP/PS1 mouse.54 Moreover, Krstic et al.25 showed
that the offspring of Poly(I:C)-challenged dams are prone to
develop an Alzheimer’s-like phenotype with aging, including
increased levels of amyloid precursor protein and its proteolytic
fragments, as well as mislocalization and hyperphosphorylation of
tau in somatodendritic compartments. To test whether the
transcriptome of microglia derived from Poly(I:C) mice display
any similarity to the transcriptional program attained by microglia
from the APP/PS1 mice, we compared the differentially expressed
Figure 5. Changes in the complement system in the hippocampus of Poly(I:C) mice. (a) Enzyme-linked immunosorbent assay (ELISA)
measurement of the complement component 4a (C4a) in whole hippocampal homogenates from Poly(I:C) (n= 5), control (n= 5) and
minocycline-treated Poly(I:C) animals (n= 4). No signiﬁcant difference in C4a levels was detected between the groups. (b) Immunoreactivity
for CD18 on microglia measured through the dentate gyrus (DG) of the hippocampus (DG) of Poly(I:C) (n= 7), controls (n= 5) and minocycline-
treated Poly(I:C) mice (n= 4). CD18 immunoreactivity in Iba1-positive cells was signiﬁcantly increased in the DG of Poly(I:C) animals as
compared with controls and minocycline-treated Poly(I:C) mice. (c) Representative pictures showing the CD18 signal co-localizing with Iba1-
positive cells (microglia) and showing the increased CD18 immunoreactivity in the proximity of the DG in Poly(I:C) animals as compared with
controls and minocycline-treated Poly(I:C) mice. Error bars represent s.e.m. in all the panels. The data were analyzed by one-way analysis of
variance (ANOVA) followed by Newman–Keuls post hoc test; *Po0.05; ctrl, control animals; NS, not signiﬁcant; Poly, Poly(I:C) animals; Poly/
Mino, Poly(I:C) animals treated with minocycline.
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genes in microglia from the Poly(I:C) mice versus control with the
differentially expressed genes in microglia from the APP/PS1 mice
versus controls (published previously40). We detected a high
correlation between the expression changes in APP/PS1 and
Poly(I:C) mice compared with controls (Pearson’s r=0.59, Figure 2d).
We identiﬁed 248 common deregulated genes in Poly(I:C) and
APP/PS1 microglia (Figure 2e). On gene ontology analysis, we found
a signiﬁcant enrichment in genes associated with phagocytosis that
conﬁrms impairment of this particular function in both animal
models; similar results were obtained in the functional phagocytosis
assay (Supplementary Table 2b). For a better view and under-
standing of the deregulated genes pertaining to different
phagocytic functions, we show a schematic representation of some
phagocytosis-associated pathways in Figure 2f.
Changes in the complement system in the hippocampus of Poly(I:
C) mice
The complement system consists of components crucial for
proper microglial-mediated phagocytosis of synapses especially
during postnatal brain development.55 In a recent study, Sekar
et al.56 demonstrated that individual variations in the allele coding
for the complement component 4 (C4) can confer high genetic
risk for schizophrenia. Microglia expresses the receptor for C4,
which is composed of both CD18 and CD11c.57 Accordingly, we
measured C4a levels via ELISA on whole hippocampal homo-
genates and the expression of CD18 by Iba1-positive cells by
ﬂuorescent immunohistochemistry to see whether they are
altered in hippocampal tissue of Poly(I:C) mice as compared with
controls. We found that C4a levels (pg/ng) were unaltered in
hippocampal tissue from Poly(I:C) mice (27.1 ± 2.4, n= 5) as
compared with controls (26.4 ± 1.8, n= 5) and Poly(I:C) mice
treated with minocycline (24.1 ± 3.5, n= 4, Figure 5a). On the
other hand, the immunoreactivity for CD18 was signiﬁcantly
increased in Iba1-positive microglia residing in the dentate gyrus
of the hippocampus of Poly(I:C) mice (0.24 ± 0.059, n= 7,
Figures 5b and c) as compared with controls (0.086 ± 0.019,
n= 5), whereas minocycline-treated Poly(I:C) animals displayed
immunoreactivity comparable to baseline level (0.057 ± 0.014,
n= 4, Figures 5b and c, one-way ANOVA F(2,13) = 4.92, P = 0.026,
Newman–Keuls post hoc test Poly versus controls and Poly versus
Poly/Mino, Po0.05).
DISCUSSION
We here demonstrate that a one-time MIA with a viral mimic
during pregnancy leads to a drastic change in transcriptome and
phagocytic activity of microglial cells in the hippocampus of the
adult offspring. These changes were associated with
schizophrenic-like behavioral abnormalities in Poly(I:C) mice.
Impaired sensory-motor gating, social interaction and memory
recollection in our study concur with similar ﬁndings in previous
studies (reviewed in refs 14,58). We further provide evidence of
how minocycline reverses the microglial alterations on the
functional and transcriptional level. Importantly, our study
revealed that behavioral deﬁcits linked with schizophrenia and
changes in microglia caused by a prenatal immune challenge can
be alleviated by adult minocycline treatment, indicating that the
developmental changes are not irreversible. This opens the
opportunity to target microglia cells in the adult as a novel
therapeutic approach for schizophrenic patients. Future research
should address the question as to whether the beneﬁcial effects of
minocycline on the behavioral, cellular and molecular level are
long-lasting once the treatment is stopped, especially regarding
microglial transcriptome signature.
Minocycline readily crosses the blood–brain barrier59 and is
already successfully used in clinical trials and impacts human
clinical data.60 Several studies have shown its complex effects on
microglia and macrophages, which depend on the particular
physiological stimulus these cells are facing.61–63 Although we
found that minocycline reversed the MIA-induced phenotype of
microglia, we are aware that it is not acting only on microglia. Its
neuroprotective action along with its inﬂuence on oligodendro-
cytes and astrocytes may participate together with its action on
microglial cells to the outcome of minocycline treatment
(reviewed in ref. 64). It is also feasible that antibiotic actions of
minocycline may inﬂuence microglial immune function in the
central nervous system indirectly via the microbiome, which has
been shown to modulate microglial cell physiology.65 The present
study did not address minocycline effects on control animals. It
would be relevant for future studies to screen the transcriptome
signature of microglia from control animals treated with
minocycline. However, in our previous study, when minocycline
was administered to both Poly(I:C) animals and control animals,
we did not observe any change of the behavioral, cellular or
molecular measures tested.23
In the present study, hippocampal microglia from male Poly(I:C)
mice displayed downregulation in expression of genes associated
with cell activation, immune response, motility and phagocytosis.
Of particular interest are the downregulated genes that encode
cell surface receptors associated with ‘pro-phagocytosis’/‘anti-
phagocytosis’ signals (Fcgr1, Itgav, P2ry6, Sirpa, Siglece, Cx3cr1).
These receptors constitute the ‘sensome’ by which microglia and
neurons communicate and they control the phagocytosis of
neurons or synapses by microglia.66 Furthermore, genes such as
Syk, Mertk, Hck, Dock1 and Elmo1 which encode proteins
controlling cytoskeletal rearrangement and phagocytosis67 were
also found to be downregulated in Poly(I:C) animals. Importantly,
two transcription factors that are crucial for microglial cell identity,
phenotype and microglia-speciﬁc functions, namely PU.1
(encoded by the gene Sfpi1) and interferon regulatory factor 8
(Irf8) were downregulated in our study.41,46,68 It was shown that
silencing of PU.1 impairs phagocytosis in human microglial
cultures.46 Comparing our data set with a recent Chip-seq study
for PU.1,41 we found a major shift of the genes that are co-
precipitated with PU.1 in Poly(I:C)-derived hippocampal microglia.
Our ex vivo phagocytosis assay validated the fact that the
phagocytic activity of hippocampal microglial cells in Poly(I:C)
offspring is signiﬁcantly decreased. We hypothesize that the
disrupted sensome and phagocytic activity in hippocampal
microglial cells participates in the behavioral dysfunctions
observed in these mice.
The downregulation of phagocytosis is contrasted by increased
expression of indicators of microglial activation, such as TSPO
binding, Iba1 immunoreactivity and IL-6 levels. TSPO binding is
not limited but mainly attributed to microglia in the current
literature. Our ﬁnding is in line with the increasing evidence of a
higher binding potential to TSPO in the brains of human
schizophrenic patients50–52 especially in the hippocampus.51
However, in general, a direct link between changes in TSPO and
microglial activation should be addressed with care. Studies have
indeed demonstrated changes in microglial TSPO expression and
binding potential in pathological conditions. Nevertheless, TSPO is
expressed also by other brain cells such as ependymal and
endothelial cells.69 In addition, we observed a stronger radioligand
binding in certain brain regions such as the brain stem and
olfactory bulbs (see Figure 4a). This is likely due to the fact that
TSPO is a mitochondrial protein responsible for the translocation
of cholesterol and, therefore, it may show different expression
patterns according to the speciﬁc metabolic needs of a particular
brain region at any given moment.
It is important to emphasize that CD18 and Iba1 were
signiﬁcantly downregulated at the mRNA level, but showed an
increased immunoreactivity at the protein level. Divergent mRNA
and protein kinetics may depend on the relative half-life of a given
mRNA versus its protein, which may not correlate.70 Our data
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show that the kinetic of protein levels might not correspond with
the kinetic of mRNA levels, which might also contribute to the
controversial ﬁndings between studies.
Previous studies utilizing the maternal immune activation
model including ours focused either on microglia density or
cytokine production.23,71–74 Although some studies including the
evaluation of human postmortem tissue reported increased
microglia density in deﬁned brain areas, others did not ﬁnd major
changes. Similar controversial data exist for cytokine levels in the
brain of patients with schizophrenia as well as in the present
animal model (reviewed in ref. 3). These differences could be
attributed to microglia heterogeneity with respect to region,
gender or age. One recent study highlighted the importance of
microglia temporal heterogeneity during development.75 A
number of studies showed that microglia attain different
transcriptional programs in distinct brain regions76–78 or differ
between male and female brains.79 Thus, when comparing data, it
is important to consider the developmental time point, the brain
region and gender as these factors might attribute to the reported
differences between the above-mentioned studies.
Microglial cell polarization is a complex matter, as it has been
demonstrated in Alzheimer’s disease where microglia can co-
express classical markers of activation concomitant with markers
of opposite, non-classically activated phenotypes.80 This is in line
with the microglia phenotype we describe in the current study: an
increase in IL-6, TSPO binding and Iba1 reactivity is accompanied
by unchanged levels of tumor necrosis factor-α and IL-1β and
impairment in phagocytosis. We have previously reported
impairment in phagocytosis of microglia associated with plaques
in the APP/PS1 model for Alzheimer’s disease using a bead-based
phagocytosis assay similar what was used in the current study.54 It
was also shown that immunotherapeutic amyloid clearance was
less effective and microglia response altered when phagocytosis
was impaired.81,82 Thus, downregulation of functional microglial
phagocytosis is a common feature in Alzheimer’s disease and MIA
models. When comparing the microglial transcriptome changes in
our model (Poly(I:C) versus control) with the changes observed in
the APP/PS1 mice (APP/PS1 versus control),40 we see a strong
overlap in genes of the phagocytosis pathway. Vav1 and Elmo
have been shown to be crucial for ﬁbrillary β-amyloid-stimulated
oxidative burst and phagocytosis.83 Considering this overlap,
especially in terms of phagocytic functions and the complex
phenotype attained by Poly(I:C) microglia, our data support the
hypothesis that early immune challenge can lead to an
Alzheimer’s-like pathology as proposed by Krstic and
colleagues.25,26 Data-driven analyses of brain structural variation
by magnetic resonance imaging revealed a network of brain
regions that spatially recapitulates the pattern of brain abnorm-
alities observed in both schizophrenia and Alzheimer’s disease.
The authors of this study suggest that the common spatial pattern
of abnormalities observed in these two disorders might be
inﬂuenced by the timing of their separate and distinct patholo-
gical processes in disrupting cerebral development and aging,
respectively.84
With respect to the complement-linked phagocytic activity, it
has been shown that complement component C3, complement
receptor type 3 and C1q contribute to the early and excessive
synaptic loss through microglia-mediated phagocytosis in a model
of Alzheimer’s disease.85 In a recent study, Sekar et al.56 found an
association between schizophrenia and variations in the major
histocompatibility complex locus on alleles affecting the expres-
sion of the complement component 4 (C4) particularly in the
hippocampus of schizophrenic patients.56 The main function of C4
is to activate the complement component 3 (C3) for proper
synaptic elimination during development, and the authors
suggest this as a mechanism by which schizophrenic individuals
exhibit decreased number of synapses in diverse brain regions in
postmortem studies.56 In our mouse model, we did not detect
changes of C4a protein in the hippocampal homogenates
between the groups, which is not surprising as the MIA mice do
not harbor a genetic C4 mutation like the human subjects.
However, changes in CD18 (part of the receptor for C3 and C4)
indicates that prenatal insult perturbs the complement system
also in the absence of genetic background, possibly participating
to the development of a defect brain micro-circuitry.
We propose that an immune challenge during prenatal
development causes changes in microglial function in adulthood
that shares common features with changes in microglial function
in neurodegenerative diseases such as Alzheimer’s disease. Early-
life events such as MIA might contribute to the neurogenic reserve
by setting the basis on how an individual might withstand
secondary challenges later in life.86 Lahiri et al.28 propose a 'Latent
Early-life Associated Regulation' model, positing latent changes in
the expression of speciﬁc genes initially primed at the develop-
mental stage of life. In this model, environmental agents
epigenetically disturb gene regulation in a long-term manner,
beginning at early developmental stages, but these perturbations
might not have pathological results until signiﬁcantly later in life.28
Our data provide evidence for this hypothesis on the level of
microglia functionality. By identifying common denominators and
traits in microglia derived from mouse models of neurodegen-
erative and psychiatric disorders, we here highlight the impor-
tance of the brain’s immune system as a target for add-on
therapeutic interventions, already starting before the onset of
symptoms.
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